Drug Trial Radar · NCT05965167
Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo
Last checked: Nov 20, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
May 11, 2023
Primary completion
Feb 8, 2026
Study completion Feb 8, 2026
Sponsor
- Lead sponsor
- Entera Bio Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 35 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize and compare the pharmacokinetics of hPTH(1 34) after treatment with modified oral formulations (EBP11, EBP11-F1, EBP11-F2, EBP11-F4, EBP11-F5 and EBP22) versus three dose levels of Entera Bio's extensively studied oral EBP05 1.5 mg, 2.5 mg and 3.0 mg as well as the commercial Forteo 0.02 mg subcutaneous injection.
Conditions
- Hypoparathyroidism
- Osteoporosis
- Fractures, Bone
- Other Disease
Interventions
EBP05Drug
Oral tablets
Forteo 0.02 mgDrug
Subcutaneous injection
EBP11Drug
Oral tablets
EBP22Drug
Oral tablets
EBP11-F2Drug
Oral tablets
EBP11-F4Drug
Oral tablets
EBP11-F1Drug
Oral tablets
EBP11-F5Drug
Oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of the pharmacokinetic profile of plasma hPTH(1-34) after single or twice daily oral administration for treatment regimen as listed under Arms and Interventions at 5, 10, 15, 20, 40, 50, 60, 75, 90, 105, 120, 180, 240, 360 min. post doseTime frame: 6 hours
- Calculation of plasma levels of hPTH(1-34) AUC0-t for each treatment regimenTime frame: 6 hours
- Calculation of plasma levels of hPTH(1-34) AUC0-inf for each treatment regimenTime frame: 6-14 hours
- Calculation of plasma levels of hPTH(1-34) AUC%extrap for each treatment regimenTime frame: 6-14 hours
- Calculation of plasma levels of hPTH(1-34) Cmax for each treatment regimenTime frame: 6-14 hours
- Calculation of plasma levels of hPTH(1-34) Tmax for each treatment regimenTime frame: 6-14 hours
- Calculation of plasma levels of hPTH(1-34) Kel for each treatment regimenTime frame: 6 hours
- Calculation of plasma levels of hPTH(1-34) t½ for each treatment regimenTime frame: 6-14 hours
- Calculation of plasma levels of hPTH(1-34) Tlast for each treatment regimenTime frame: 6-14 hours
- Assessment of inter-subject variability of hPTH(1-34) for each treatment regimenTime frame: 6-14 hours
- Calculation of dose proportionality for hPTH(1-34) for relevant treatment regimenTime frame: 6 hours
- Assessment of the duration of exposure to hPTH(1-34) in minutesTime frame: 6 hours
- Vital Signs - body temperature (Celsius)Time frame: 6 hours
- Vital Signs - respiratory rate (breaths per minute)Time frame: 6 hours
- Vital Signs - blood pressure (systolic/diastolic mmHg)Time frame: 6 hours
- Vital Signs - heart rate (beats per minute)Time frame: 6 hours
- Incidence of Treatment-Emergent Adverse Events as assessed by the Principle InvestigatorTime frame: 6-14 hours
- Incidence of Serious Adverse Events (SAEs) as assessed by the Principle InvestigatorTime frame: 6-14 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Research Center Hadassah Ein Kerem Medical Center
Jerusalem, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.